{
    "title": "115_hr5687",
    "content": "The Act titled \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act\" introduces safety-enhancing packaging and disposal features for certain drugs under the Federal Food, Drug, and Cosmetic Act. The Secretary may issue orders requiring the implementation of technologies to mitigate abuse or misuse of drugs listed in a covered application, after consulting with stakeholders to ensure access and minimize burden. The Secretary may issue orders to implement technologies to reduce the risk of drug abuse or misuse listed in a covered application. The orders should be proportionate to the specific risk, not overly restrictive on patient access, and aim to decrease the risk of abuse or misuse. The order may offer various options for implementing the required technologies and may reference packaging or disposal standards from an official compendium. The Secretary may issue orders to reduce drug abuse or misuse risks in a covered application. Orders must be proportionate, not overly restrictive, and aim to decrease risks. Orders may reference packaging or disposal standards from an official compendium. Compliance requires submitting proposed changes within 180 days. The Secretary may issue orders to reduce drug abuse risks in a covered application, requiring proposed changes to be submitted within 180 days and implemented within 90 days of approval. Requests for alternative dates can be made within 60 days of the order issuance. The Secretary may approve alternative technologies, controls, or measures for packaging, storage, or disposal in a covered application if supported by data to mitigate abuse or misuse risks. The Secretary may approve alternative technologies, controls, or measures for packaging, storage, or disposal in a covered application if supported by data to mitigate abuse or misuse risks. Dispute resolution procedures are available for appeals regarding determinations on such supplements. The term 'relevant stakeholders' includes various experts and organizations in the drug industry, such as manufacturers, wholesalers, healthcare providers, and government agencies. Prohibited acts are outlined in Section 501 of the Federal Food, Drug, and Cosmetic Act. The curr_chunk discusses amendments to the Federal Food, Drug, and Cosmetic Act related to drug approval requirements and the content of Abbreviated New Drug Applications. It includes provisions regarding opioids and the Controlled Substances Act. The curr_chunk discusses amendments to the Federal Food, Drug, and Cosmetic Act related to drug approval requirements, including provisions regarding opioids and the Controlled Substances Act. It mentions requirements for proposed technologies, controls, or measures related to packaging or disposal of drugs. The curr_chunk discusses amendments to the Federal Food, Drug, and Cosmetic Act related to drug approval requirements, including provisions regarding opioids and the Controlled Substances Act. It mentions requirements for proposed technologies, controls, or measures related to packaging or disposal of drugs, including labeling restrictions to mitigate abuse or misuse risks. The curr_chunk clarifies that certain changes to drug labeling and conditions of use under the Federal Food, Drug, and Cosmetic Act do not affect approval of new drug applications. It also states that data limitations do not apply to covered applications submitted under specific sections of the Act. The curr_chunk discusses the Secretary of Health and Human Services' authority to request data for making determinations under section 505-2. It also mentions a GAO report due within 12 months on the effectiveness of in-home controlled substance disposal products and packaging technologies, along with identifying barriers to their use. The curr_chunk provides details on the oversight of controlled substance disposal products and packaging technologies, including federal agencies involved, recommended disposal methods, and effectiveness in preventing diversion of prescribed substances. The curr_chunk discusses federal oversight of controlled substance disposal products and packaging technologies, including recommended technologies and their effectiveness in preventing diversion of prescribed substances. Recommendations are also provided on the need for federal oversight of in-home disposal products and the role of the Federal Government in evaluating product efficacy. The curr_chunk states that the bill was passed by the House of Representatives on June 19, 2018, with Karen L. Haas as the Clerk."
}